Report
TheraVet - H1 23 business update
TheraVet published a business update. The company comes back on the progress made during H1 23. One of the main events was the commercial launch of BIOCERA-VET combined with antibiotics. Moreover, the update highlights that no further delays are currently foreseen in the EU study evaluating VISCO-VET. Given the 12-15 months delay announced, we expect enrollment to be completed soon with interim results to be published by the end of the year. TheraVet is expanding its offering with the development of a new version of BIOCERA-VET to be combined with chemotherapeutics, further reinforcing its market position.
Underlying
TheraVet
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Laura Roba
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.